Special Considerations in the Management of HIV-Infected Women, Including Management of Conception and Pregnancy
Source: Clinical Resources From inPractice HIV

Module

Kristine Patterson, MD, discusses specific topics to consider in the clinical care of HIV-infected women in different life stages, including treatment-related issues and complications specific to HIV-infected women.

Learning Objectives

Upon completion of this activity, participants should be able to:

Topics covered include:

  • Introduction
  • Primary Care of HIV-Infected Women
  • Overview of Health Considerations: Reproductive Health
  • Sexually Transmitted Diseases in HIV-Infected Women
  • Cervical Cancer Screening in HIV-Infected Women
  • Antiretroviral Therapy in HIV-Infected Women
  • Depression and HIV-Infected Women
  • Care of Pregnant HIV-Infected Women
  • Care of Menopausal HIV-Infected Women
 

Program Directors

  • Joseph J. Eron, Jr.
    MD
    Daniel R. Kuritzkes
    MD
    Kathleen E. Squires
    MD
    Judith S. Currier
    MD, MSc

Faculty

  • Kristine Patterson
    MD
  • Release Date:
    January 20, 2017

Information on this Educational Activity

Program Directors

Joseph J. Eron, Jr., MD

Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and ViiV; consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, Roche Molecular Systems, Tibotec/Janssen, and ViiV; and has served on the data and safety monitoring board for TaiMed.

 

Daniel R. Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Bionor, Gilead Sciences, GlaxoSmithKline, InnaVirVax, Janssen, Merck, Oncolys, Teva, ViiV, and ViroStatics; fees for non-CME/CE services from Merck; and funds for research support from Gilead Sciences.

 

Kathleen E. Squires, MD

W. Paul and Ida H. Havens Professor of Infectious Diseases
Director,
Division of Infectious Diseases
Sidney Kimmel Medical College of Thomas Jefferson University
Philadelphia, Pennsylvania

Kathleen E. Squires, MD, has disclosed that she has served on advisory boards for scientific purposes for Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV; has served on advisory boards for marketing purposes for Gilead Sciences and Janssen; and has received funds for research support from Gilead Sciences.

 

Judith S. Currier, MD, MSc

Professor of Medicine
Chief, Division of Infectious Diseases
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California

Judith S. Currier, MD, MSc, has no real or apparent conflicts of interest to report.

 

Faculty

Kristine Patterson, MD


Associate Professor of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Kristine Patterson, MD, has disclosed that she has received salary from AbbVie.
 

Staff

Rachael M. Andrie, PhD


Clinical Editor

Rachael M. Andrie, PhD, has nothing to disclose with regard to commercial interests.
 

Jennifer M. Blanchette, PhD


Managing Editor

Jennifer M. Blanchette, PhD, has nothing to disclose with regard to commercial interests.
 

Edward King, MA


Chief Innovation Officer

Edward King, MA, has nothing to disclose with regard to commercial interests.
 

Jenny Schulz, PhD


Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has nothing to disclose with regard to commercial interests.
 

Zachary Schwartz, MSc, ELS


Managing Editor

Zachary Schwartz, MSc, ELS, has nothing to disclose with regard to commercial interests.
 

Heather Stieglitz, PhD


Editorial Contributor

Heather Stieglitz, PhD, has nothing to disclose with regard to commercial interests.
 

  • Clinical Case: Estimating Cardiovascular Disease Risk With the ASCVD Event Calculator

    David A. Wohl MD - 9/16/2015    1 comment / Last Comment: 9/17/2015
    How I used the ASCVD event calculator to estimate CVD risk for an HIV-infected patient with stably suppressed HIV-1 RNA.
  • My Approach to First-line ART for Patients With High Cardiovascular Disease Risk

    William G. Powderly MD - 10/6/2015    4 comments / Last Comment: 11/8/2015
    When treating HIV in patients with risk factors for CVD, selecting the optimal ART regimen is only part of the equation.
  • Selecting First-line Antiretroviral Therapy in Older Patients: New Data, New Options, Key Considerations

    Giovanni Guaraldi MD - 12/16/2015    2 comments / Last Comment: 2/10/2016
    The management of ART in patients aging with HIV requires clinicians to maintain a detailed knowledge of physical and psychological patient health in order to tailor the most appropriate ART regimen.
  • Why ART Trials Specific to Women Are Important

    Kathleen E. Squires MD - 9/28/2016    2 comments / Last Comment: 10/19/2016
    Although almost one half of new HIV infections worldwide occur in women, to date, clinical trials for FDA-approved ART regimens have largely been conducted in men. Here is my take on why women-specific ART trials are important.
  • ART in Older Patients: How I Manage Drug–Drug Interactions With Concomitant Medications

    Anton L. Pozniak MD, FRCP - 10/20/2015    16 comments / Last Comment: 5/10/2016
    As our patients age, they experience metabolic changes and more frequently develop conditions such as bone mineral density loss, cardiovascular disease, diabetes, and malignancies, all of which will affect the choice of first-line ART.